Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Randomized Double-Blind Trial of Baricitinib or Placebo Combined With Antiviral Therapy in Patients With Moderate and Severe COVID-19

Trial Profile

A Phase II Randomized Double-Blind Trial of Baricitinib or Placebo Combined With Antiviral Therapy in Patients With Moderate and Severe COVID-19

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Jun 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Baricitinib (Primary) ; Hydroxychloroquine (Primary) ; Lopinavir/ritonavir (Primary) ; Remdesivir (Primary)
  • Indications COVID 2019 infections; Respiratory tract infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 May 2020 Planned End Date changed from 24 Apr 2022 to 1 May 2022.
    • 30 May 2020 Planned primary completion date changed from 24 Apr 2021 to 1 May 2021.
    • 19 May 2020 Study design has changed from single group assignment to parallel assignment, treatment has amendment and patient number has also increased.
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top